Instrument dashboard

NEUROCRINE BIOSCIENCES INC (NBIX)

NASDAQ · US

NBIX · Market chart

Loading chart…

Latest Pine script: 2026-11-20

Market structure

PRICE LEVEL INTELLIGENCE

Reference close · 2026-11-20
LEVEL / SOURCEPRICE LEVELPRICE
Primary ascending broadening lower boundaryTECHNICAL · Anchors: 2026-02-12 low 122.13 and 2026-10-14 low 132.25. x is elapsed 24-hour periods since 2026-02-12 00:00 America/New_York, calculated as (bar timestamp - anchor timestamp)/86400000. The projected value on 2026-11-19 is approximately 133.75. The latest close of 156.59 is above the projected boundary, making it structural support.
—
Primary ascending broadening upper boundaryTECHNICAL · Anchors: 2025-11-05 high 157.67 and 2026-07-30 high 186.12. x is elapsed 24-hour periods since 2025-11-05 00:00 America/New_York, calculated as (bar timestamp - anchor timestamp)/86400000. The projected value on 2026-11-19 is approximately 198.06. The latest close of 156.59 is below the projected boundary, making it overhead resistance.
—
Secondary descending resistanceTECHNICAL · Anchors: 2026-09-02 high 160.43 and 2026-10-05 high 146.92. x is elapsed 24-hour periods since 2026-09-02 00:00 America/New_York, calculated as (bar timestamp - anchor timestamp)/86400000. The descending trajectory is supported by repeated historical interactions with intervening highs. Its projected value on 2026-11-19 is approximately 128.48. The latest close of 156.59 is above the projected line, which now lies below market price.
—
2xATR Support 122.13-134.50TECHNICAL · Control bar: 2026-02-12, high 134.50 and low 122.13. True range was 15.31 against Wilder ATR(14) of 4.70, approximately 3.26 times ATR. The lower boundary coincides with the primary structural lower-boundary anchor on the same date, and the region contains the 125.53 monthly S2 reference. The 2026-11-19 close of 156.59 is above the upper boundary, so the region currently acts as support.
122.13 – 134.50
2xATR Support 141.96-148.98TECHNICAL · Control bar: 2026-05-06, high 148.98 and low 141.96. True range was 13.92 against Wilder ATR(14) of 4.39, approximately 3.17 times ATR. The region contains the independently calculated monthly P reference of 142.53. The 2026-11-19 close of 156.59 is above the upper boundary, so the region currently acts as support.
141.96 – 148.98
2xATR Disputed 147.60-157.67TECHNICAL · Control bar: 2025-11-05, high 157.67 and low 147.60. True range was 14.48 against Wilder ATR(14) of 4.91, approximately 2.95 times ATR. The upper boundary exactly coincides with the primary upper structural anchor on 2025-11-05. The region also contains the monthly R1 reference of 152.82. The 2026-11-19 close of 156.59 is inside the region, so its current role is disputed.
147.60 – 157.67
2xATR Resistance 158.01-169.52TECHNICAL · Control bar: 2026-11-03, high 169.52 and low 158.01. True range was 24.17 against Wilder ATR(14) of 4.90, approximately 4.93 times ATR. The upper boundary is closely aligned with monthly R3 at 169.82, and the region contains monthly R2 at 159.53. The 2026-11-19 close of 156.59 is below the lower boundary, confirming a breakdown of the entire region and its current resistance role.
158.01 – 169.52
2xATR Resistance 164.56-185.55TECHNICAL · Control bar: 2026-07-31, high 185.55 and low 164.56. True range was 20.99 against Wilder ATR(14) of 6.32, approximately 3.32 times ATR. The region contains the monthly R3 reference of 169.82, while its upper boundary is closely aligned with the primary upper structural anchor of 186.12 from 2026-07-30. The 2026-11-19 close of 156.59 is below the lower boundary, so the region currently acts as resistance.
164.56 – 185.55
Monthly S2TECHNICAL · Calculated from completed October 2026 using P = 142.533333, H = 149.25 and L = 132.25. Traditional pivot calculation: S2 = P - H + L = 125.53. The 2026-11-19 close of 156.59 is above the level, so it currently acts as support.
125.53
Monthly S1TECHNICAL · Calculated from completed October 2026 using P = 142.533333 and H = 149.25. Traditional pivot calculation: S1 = 2P - H = 135.82. The 2026-11-19 close of 156.59 is above the level, so it currently acts as support.
135.82
Monthly PTECHNICAL · Calculated from completed October 2026: high 149.25, low 132.25 and close 146.10. Traditional pivot calculation: P = (H + L + C)/3 = 142.53. The 2026-11-19 close of 156.59 is above the level, so it currently acts as support.
142.53
Analyst 12-month low targetANALYST · Lowest analyst 12-month price target
150.00
Monthly R1TECHNICAL · Calculated from completed October 2026 using P = 142.533333 and L = 132.25. Traditional pivot calculation: R1 = 2P - L = 152.82. The 2026-11-19 close of 156.59 is above the level, so it currently acts as support.
152.82
Monthly R2TECHNICAL · Calculated from completed October 2026 using P = 142.533333, H = 149.25 and L = 132.25. Traditional pivot calculation: R2 = P + H - L = 159.53. The 2026-11-19 close of 156.59 is below the level, so it currently acts as resistance.
159.53
Monthly R3TECHNICAL · Calculated from completed October 2026 using P = 142.533333 and L = 132.25. Traditional pivot calculation: R3 = H + 2(P - L) = 169.82. The 2026-11-19 close of 156.59 is below the level, so it currently acts as resistance.
169.82
Analyst 12-month median targetANALYST · Median analyst 12-month price target
215.00
Analyst 12-month high targetANALYST · Highest analyst 12-month price target
253.00
GEX put wall · 2026-12-18GEX · Options positioning
145.00
GEX call wall · 2026-12-18GEX · Options positioning
155.00

Sign in to view price levels

Technical, analyst and options-derived levels are available to signed-in members.

Sign in
AI-Ready Research Pack

Download the available financial metrics, calculation methodology and latest technical price levels for NBIX.

Download research pack
Files included for this instrument:
  • SEC financial metrics calculation guide
  • Financial metrics for the current year
  • Technicals and future GEX levels
Company fundamentals

Financial health

Revenue••••••Profitability••••••Cash flow••••••Capital structure••••••
Available reporting years2026, 2025

Sign in to request beta access

Financial health insights are in a limited beta.

Sign in
Valuation framework

Valuation

Midpoint fair value••••••
Cash Flow DCF••••••
Revenue unit economics••••••
Reporting periods: 3 quarters available

Sign in to request beta access

Valuation tools are in a limited beta.

Sign in